Sorrento Therapeutics, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a SRNEQ research report →
Price Chart
About the company
Sorrento Therapeutics, Inc. is a biopharmaceutical firm that has both clinical-stage and commercial products. It concentrates on developing cutting-edge therapies across three main health domains: oncology, infectious diseases, and pain management.
- CEO
- Henry H. Ji
- IPO
- 2007
- Employees
- 949
- HQ
- San Diego, CA, US
Get TickerSpark's AI analysis on SRNEQ
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $16.54M
- P/E
- -0.00
- PEG
- -0.00
- P/S
- 0.01
- P/B
- -0.02
- EV/EBITDA
- -0.21
- Div Yield
- 0.00%
- Gross Margin
- 46.77%
- Op Margin
- -802.55%
- Net Margin
- -911.60%
- ROE
- -1904.94%
- ROIC
- -286.80%
- 52W High
- $0.42
- 52W Low
- $0.00
- 50D MA
- $0.02
- 200D MA
- $0.09
- Beta
- 2.29
- RSI (14)
- 49
- Avg Volume
- 329.98K
No earnings-call transcripts are available for SRNEQ yet.
- Free Float
- 97.8%
- Shares Outstanding
- 551.28M
- Float Shares
- 538.99M
Our SRNEQ coverage
Recent articles, reports, and earnings notes.
No research on SRNEQ yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate SRNEQ report →Reviewing SQZ Biotechnologies (NYSE:SQZ) and Sorrento Therapeutics (OTCMKTS:SRNEQ)
defenseworld.net · Jan 12
Sorrento Therapeutics (OTCMKTS:SRNEQ) versus LadRx (OTCMKTS:CYTR) Financial Contrast
defenseworld.net · Dec 31
Contrasting Sorrento Therapeutics (OTCMKTS:SRNEQ) and LadRx (OTCMKTS:CYTR)
defenseworld.net · Dec 13
Sorrento Therapeutics (OTCMKTS:SRNEQ) and bluebird bio (NASDAQ:BLUE) Financial Comparison
https://www.defenseworld.net · May 20
Sorrento Therapeutics, Inc. Announces the Consummation of the Previously Announced Sale of Substantially All of the Common Shares, Preferred Shares and Warrants that Sorrento Held in Scilex Holding Company
prnewswire.com · Sep 22
Sorrento Announces Phase 3 Trial Met Primary Endpoint and Key Secondary Endpoint in Mild or Moderate COVID-19 Adult Patients Treated with Ovydso (Olgotrelvir), an Oral Mpro Inhibitor as a Standalone Treatment for COVID-19
globenewswire.com · Sep 12
Sorrento Therapeutics Announces Positive Phase 2a Clinical Trial Results for Resiniferatoxin (RTX) for the Treatment of Knee Pain in Moderate to Severe Osteoarthritis of the Knee (OAK) Patients
globenewswire.com · Sep 7
Sorrento Issues a “FAQ” in Response to Large Number Of Urgent Requests from Scilex Dividend Short Holders and/or Record Holders
globenewswire.com · Jul 27
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.